Elizabeth Bhatt
CIK 1748622 · President and COO · last filed 2026-07-17
Elizabeth Bhatt is a President and COO who has filed 23 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for SEPN, was dated Jul 17, 2026. Across all open-market trades the lifetime net is −$1.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.92M
5
23
-$1.04M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SEPN | President and COO | 174,209 | $33.97 | $5.92M | -$349.2K | 5 | 2026-07-17 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Director | 9,047 | $0.00 | $5 | $0 | 7 | 2024-06-13 |
| Applied Molecular Transport Inc. (AMTI) Delisted | Chief Bus. & Strategy Officer | 48,750 | $0.26 | $12.8K | -$694.7K | 5 | 2022-02-16 |
| LWACU | Director | — | $10.32 | — | $0 | 1 | 2021-01-14 |
| Achaogen, Inc. (AKAO) Delisted | Chief Operating Officer | 238,155 | — | — | -$864 | 3 | 2019-02-25 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-17 | SEPN | Mixed | — | -$108.7K | EDGAR |
| 2026-07-15 | SEPN | Notice (144) | −4,000 | -$138.2K | EDGAR |
| 2026-04-17 | SEPN | Mixed | — | -$70.1K | EDGAR |
| 2026-02-20 | SEPN | Mixed | — | -$88.6K | EDGAR |
| 2026-02-18 | SEPN | Notice (144) | −8,000 | -$242.4K | EDGAR |
| 2026-02-10 | SEPN | Grant (A) | — | $0 | EDGAR |
| 2025-08-11 | SEPN | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-21 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-22 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.